Tetikoğlu Mehmet, Kurt Muhammed Mustafa, Sağdık Hacı Murat, Aktaş Serdar, Yıldırım Medine Aslı, Özcura Fatih
a Department of Ophthalmology , Dumlupinar University School of Medicine , Kutahya , Turkey.
b Department of Ophthalmology , Samsun Gazi State Hospital , Samsun , Turkey.
Cutan Ocul Toxicol. 2018 Mar;37(1):84-89. doi: 10.1080/15569527.2017.1354217. Epub 2017 Jul 28.
To evaluate the effects of intravitreal aflibercept (IVA) on retinal vessel diameters in patients with neovascular age-related macular degeneration (AMD).
DESIGN, SETTING, AND PARTICIPANTS: A retrospective study conducted at the Kutahya Dumlupinar University Faculty of Medicine included 15 eyes of 15 patients with treatment naive neovascular AMD.
All eyes received IVA injections once per month for 3 months; untreated contralateral eyes were used as controls. The central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and artery-vein ratio (AVR) values were measured using a computer-based program before the first IVA injection and 30 days after the first, second, and third injections. The main outcome measurements were the central macular thickness (CMT), best-corrected visual acuity (BCVA), choroidal thickness, CRAE, CRVE, and AVR.
Significant vasoconstriction of the retinal arterioles was observed in all eyes treated with IVA when compared to baseline (p = 0.009). However, no significant differences were found for CRVE or AVR throughout the study period in treated eyes. In the control group, all parameters measured during each visit were similar to baseline measurements (p > 0.05). The mean BCVA significantly improved at the end of the loading dose of IVA, when compared to baseline (p = 0.006). After the IVA injections, the mean CMT and choroidal thickness were significantly reduced at all visits, compared to baseline (p < 0.001).
The current study showed that IVA led to significant retinal arteriolar vasoconstriction and choroidal thinning, which may cause reduced retinal blood flow.
评估玻璃体内注射阿柏西普（IVA）对新生血管性年龄相关性黄斑变性（AMD）患者视网膜血管直径的影响。
设计、设置和参与者：在库塔希亚杜姆卢皮纳尔大学医学院进行的一项回顾性研究，纳入了15例初治新生血管性AMD患者的15只眼。
所有眼睛每月接受一次IVA注射，共3个月；未治疗的对侧眼作为对照。在首次IVA注射前以及首次、第二次和第三次注射后30天，使用基于计算机的程序测量视网膜中央动脉等效直径（CRAE）、视网膜中央静脉等效直径（CRVE）和动静脉比（AVR）值。主要观察指标为中心黄斑厚度（CMT）、最佳矫正视力（BCVA）、脉络膜厚度、CRAE、CRVE和AVR。
与基线相比，所有接受IVA治疗的眼睛均观察到视网膜小动脉明显收缩（p = 0.009）。然而，在整个研究期间，治疗眼的CRVE或AVR没有显著差异。在对照组中，每次随访时测量的所有参数与基线测量值相似（p > 0.05）。与基线相比，在IVA负荷剂量结束时，平均BCVA显著改善（p = 0.006）。与基线相比，在IVA注射后，所有随访时的平均CMT和脉络膜厚度均显著降低（p < 0.001）。
当前研究表明，IVA导致视网膜小动脉明显收缩和脉络膜变薄，这可能导致视网膜血流减少。
